Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2021

View Archived Issues

Aberrant NAD+ metabolism underlies Zika microcephaly

Phase II study initiated to assess aspacytarabine in AML and MDS patients

Moderna initiates phase I/II study of mRNA-3705 for methylmalonic acidemia

Chengdu Biobel patents compounds for C. difficile infection

Chinese researchers divulge new PD-1/PD-L1 interaction inhibitors

Jasan Bio Medicine (Jiaxing) synthesizes new DHFR inhibitors

Clinical trial finds PRAX-114 improves symptoms of perimenopausal depression

AgeX Therapeutics describes new exosomes for wound healing

Neurodevelopmental disorders tied to genetic variation in CLCN3 gene

Inhibitors of TNF-alpha- and IL-6-induced adhesion show activity in IBD models

BBP-631 enters phase I/II for treating congenital adrenal hyperplasia

Initiation of phase II trial to assess TLX-66 for pediatric leukemia

Phase II study cleared to evaluate TQ Formula in COVID-19 patients

TRIDENT-2 study evaluates repotrectinib combined with trametinib in KRAS G12D mutant solid tumors

IND application accepted for phase I/Ib trial for CPI-818 for treating R/R T-cell lymphoma in China

Crovalimab evaluated for vaso-occlusive episodes in patients with sickle cell disease

Green light for censavudine to initiate phase II trial in neurodegeneration

Transient nanofibrillar hydrogels release glucagon under low-glucose conditions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...